{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:03:10Z","timestamp":1790874190740,"version":"4.1.0"},"reference-count":13,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100024879","name":"Janssen Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024879","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The MYLENE non\u2010interventional study (NIS) aimed to close the gap in real\u2010world data on the experience and satisfaction with subcutaneous (sc) and intravenous (iv) daratumumab application in patients with newly diagnosed non\u2010transplant eligible multiple myeloma in Germany. The study specifically focused on satisfaction among both patients and healthcare providers (HCP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>MYLENE was a prospective, multicenter NIS in Germany, designed to evaluate patient and HCP satisfaction with sc and iv daratumumab administration via study\u2010specific, non\u2010standardized questionnaires, as well as patient safety data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between 2022 and 2023, 108 patients were enrolled at 34 sites; 96 were included in the full analysis set (38 iv, 48 sc, 10 switchers); due to the low switcher rate, conclusions regarding this subgroup are very limited. Median age was 76\u2009years. Patients were highly satisfied with their daratumumab treatment (median rating 9 on a 1\u201310 scale). Overall HCP satisfaction level was higher for sc (9) than iv (7), and HCPs reported higher satisfaction with sc administration time and patient visit duration. No new safety signals were detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MYLENE provides insights into the practical management of daratumumab administration in office\u2010based settings in Germany. Patients reported high satisfaction with both sc and iv administration. The study highlights a preference among HCPs for sc administration, primarily due to reduced time requirements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>NCT05284591<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ejh.70333","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:02:13Z","timestamp":1790859733000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient and Healthcare Provider Satisfaction With Subcutaneous Versus Intravenous Administration of Daratumumab in Combination With Lenalidomide and Dexamethasone as First\u2010Line Treatment in Patients With Newly Diagnosed Non\u2010Transplant Eligible Multiple Myeloma: Final Results of the\n                    <scp>MYLENE<\/scp>\n                    Study"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0996-0261","authenticated-orcid":false,"given":"Eyck","family":"von der Heyde","sequence":"first","affiliation":[{"name":"Onkologische Schwerpunktpraxis  Hannover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0457-7793","authenticated-orcid":false,"given":"Marcel","family":"Reiser","sequence":"additional","affiliation":[{"name":"PIOH \u2013 Praxis Internistische Onkologie Und H\u00e4matologie  K\u00f6ln Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Baumgartner","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag GmbH  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Englisch","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag GmbH  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Frank","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag GmbH  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Buchholz","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag GmbH  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Kreimendahl","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag GmbH  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Uhlig","sequence":"additional","affiliation":[{"name":"Onkologische Praxis  Naunhof Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"B\u00fcrkle","sequence":"additional","affiliation":[{"name":"Zentrum Ambulante Onkologie  Schorndorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Knauf","sequence":"additional","affiliation":[{"name":"Wissenschaftliches Institut der Niedergelassenen H\u00e4matologen und Onkologen GmbH (WINHO)  K\u00f6ln Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"Janssen\u2010Cilag Ltd \u201cDARZALEX Summary of Product Characteristics [Internet] \u201d(2025) https:\/\/www.medicines.org.uk\/emc\/product\/11488\/smpc#gref."},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30070-3"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279459"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03365-w"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00366-3"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.11194"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02985-9"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3147-y"},{"key":"e_1_2_12_10_1","unstructured":"Research C for DE and \u201cFDA Approves Atezolizumab and Hyaluronidase\u2010Tqjs for Subcutaneous Injection \u201d(2024) FDA [Internet] https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010atezolizumab\u2010and\u2010hyaluronidase\u2010tqjs\u2010subcutaneous\u2010injection."},{"key":"e_1_2_12_11_1","unstructured":"Research C for DE and \u201cFDA Approves Nivolumab and Hyaluronidase\u2010Nvhy for Subcutaneous Injection \u201d(2024) FDA [Internet] https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010nivolumab\u2010and\u2010hyaluronidase\u2010nvhy\u2010subcutaneous\u2010injection."},{"key":"e_1_2_12_12_1","unstructured":"\u201cMerck's Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous (IV) KEYTRUDA (pembrolizumab) in Pivotal 3475A\u2010D77 Trial [Internet] \u201d(2025) https:\/\/www.merck.com\/news\/mercks\u2010investigational\u2010subcutaneous\u2010pembrolizumab\u2010with\u2010berahyaluronidase\u2010alfa\u2010demonstrates\u2010noninferior\u2010pharmacokinetics\u2010compared\u2010to\u2010intravenous\u2010iv\u2010keytruda\u2010pembrolizumab\u2010in\u2010pivotal\/."},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202406604"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP-25-00052"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70333","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.70333","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70333","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:25:19Z","timestamp":1790871919000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":13,"alternative-id":["10.1111\/ejh.70333"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70333","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"2026-05-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ejh.70333"}}